#VisualAbstract Aflibercept Biosimilar MYL-1701P vs. Aflibercept in Diabetic Macular Edema
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. In patients with diabetic macular edema, aflibercept monotherapy showed no difference in vision improvement compared to step therapy of ...
1. In both trials, faricimab was demonstrated to be non-inferior to aflibercept at improving visual acuity in neovascular age-related macular ...
1. Faricimab every 8 weeks and faricimab per personalized treatment interval (PTI) were noninferior to aflibercept for mean change in ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.